Sanofi's Dupixent shows promise in urticaria treatment

Sanofi (NASDAQ:SNY) has announced significant findings from a phase 3 trial of Dupixent in treating chronic spontaneous urticaria, an inflammatory skin condition.

The study revealed that 41% of participants achieved well-controlled disease status, with substantive reductions in itch and hive activity.

"These data confirm results seen in the previous Study A and reinforce the potential of Dupixent to significantly alleviate symptoms for patients," noted Dr. Thomas B. Casale, Professor of Internal Medicine at the University of South Florida.

The results were presented at the ACAAI 2024 Annual Scientific Meeting.

Dupixent, a fully human monoclonal antibody, is being reviewed for regulatory approval in the U.S. and Europe following its use showing promise in populations inadequately controlled by antihistamines.

The treatment has already been approved for CSU in Japan and the UAE.

Safety results in the study were consistent with expectations.

If U.S. approval is secured, Dupixent would become the first new targeted treatment for CSU in more than a decade, potentially benefiting over 300,000 Americans affected by this condition.